Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

v3.24.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)
3 Months Ended 9 Months Ended
Jan. 31, 2024
Jan. 31, 2023
Jan. 31, 2024
Jan. 31, 2023
Income Statement [Abstract]        
Revenue $ 0 $ 0 $ 0 $ 0
Operating expenses:        
Research and development costs 126,732 45,393 313,248 382,662
Compensation expense 620,777 251,556 1,089,934 979,694
Director fees 638,762 795,969 995,715 951,031
Legal and professional 230,772 103,180 1,075,073 2,454,227
General and administrative 251,903 356,885 1,879,822 784,597
Total operating expenses 1,868,946 1,552,983 5,353,792 5,552,211
Loss from operations (1,868,946) (1,552,983) (5,353,792) (5,552,211)
Other income (expenses):        
Interest income 881,662 635,889 2,651,721 1,214,562
Change in fair value of warrant liability 10,000 0 2,633,000 0
Change in fair value of derivative liability 636,000 0 (663,000) 0
Change in fair value of convertible note receivable 138,000 0 138,000 0
Change in fair value of warrant asset (416,000) 0 (416,000) 0
Other income (expense), net (253) 152,958 (2,867) 147,994
Total other income, net 1,249,409 788,847 4,340,854 1,362,556
Net loss (619,537) (764,136) (1,012,938) (4,189,655)
Preferred stock dividends (781,507) 0 (1,688,242) 0
Preferred stock accretion (4,219,069) 0 (11,995,681) 0
Net loss attributable to common stockholders $ (5,620,113) $ (764,136) $ (14,696,861) $ (4,189,655)